Varano, Susann
Staskin, David
Frankel, Jeffrey
Shortino, Denise
Jankowich, Rachael
Mudd, Paul N. Jr
Clinical trials referenced in this document:
Documents that mention this clinical trial
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
https://doi.org/10.1007/s12325-021-01972-8
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
https://doi.org/10.1007/s40266-020-00829-z
Funding for this research was provided by:
Urovant Sciences
Article History
Accepted: 28 November 2020
First Online: 20 January 2021
Declarations
:
: This study and medical writing and editorial support for the preparation of this manuscript were funded by Urovant Sciences (Irvine, CA).
: S. Varano is principal investigator for Clinical Research Consulting and adjunct professor at Sacred Heart University and University of Bridgeport. D. Staskin is an investigator and consultant for Urovant Sciences; a consultant, investigator, and speaker for Astellas Pharma; and a consultant for New Uro B.V. J. Frankel is an investigator for Urovant Sciences, an investigator and speaker for Astellas Pharma and Pfizer Inc., and a speaker for Tolmar Inc. D. Shortino, R. Jankowich, and P.N. Mudd Jr are employees of Urovant Sciences and may be shareholders.
: The EMPOWUR study was conducted in compliance with Good Clinical Practice. Institutional review board, research ethics board, or independent ethics committee was obtained before study initiation. All patients provided written informed consent.
: Request for data from Urovant Sciences (email: medinfo@urovant.com) will be considered from qualified researchers on a case-by-case basis.